SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 26 2023
0mins
Source: PRnewswire
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 289.890
Low
270.00
Averages
304.45
High
325.00
Current: 289.890
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Labcorp Launches Alzheimer's Blood Test Nationwide
- Innovative Testing Tool: Labcorp's Elecsys® pTau-181 test is the first blood test cleared by the FDA for initial Alzheimer's disease assessment, enabling clinicians to rule out patients' Alzheimer's likelihood more quickly, thereby enhancing patient care efficiency.
- Wide Applicability: The test is now available nationwide in primary care settings, specifically designed for patients aged 55 and older experiencing cognitive decline symptoms, significantly expanding Labcorp's comprehensive portfolio of Alzheimer's blood tests.
- High Predictive Capability: The Elecsys pTau-181 test offers a 97.9% negative predictive value, allowing clinicians to confidently rule out Alzheimer's pathology, which is crucial in reducing unnecessary referrals amid a national shortage of neurologists.
- Convenient Testing Method: The test is performed via a simple blood draw, which can be done in a doctor's office or at any of Labcorp's over 2,200 patient service centers, providing a more accessible and cost-effective alternative to traditional brain scans or lumbar punctures.
See More
Labcorp Launches First Blood Test for Alzheimer's Disease
- First Blood Test: Labcorp's Elecsys® pTau-181 test is the first blood test cleared by the FDA for the initial assessment of Alzheimer's disease, representing a significant breakthrough in primary care that enables earlier identification of patient conditions.
- Expanded Testing Access: This test allows primary care clinicians to quickly rule out Alzheimer's disease when patients present cognitive symptoms, thereby enhancing patient care efficiency and reducing reliance on specialists, optimizing healthcare resource allocation.
- Market Demand Response: With approximately 7.2 million Americans living with Alzheimer's disease, Labcorp's launch of this test addresses the urgent need for early diagnosis and assessment, further solidifying its leadership position in the blood testing market for Alzheimer's disease.
- Research Support: Labcorp has supported over 90 Alzheimer's disease research protocols in the past five years, showcasing its deep expertise in biomarker development aimed at advancing early diagnosis and treatment progress for Alzheimer's disease.
See More
Labcorp Appoints New Board Member
- New Board Member: Labcorp appointed Dr. John H. Sampson to its Board of Directors effective February 9, 2026, bringing extensive experience in medicine and biomedical research, which is expected to advance the company's strategy in diagnostics and drug development.
- Professional Background: Dr. Sampson previously served as vice chancellor and dean at the University of Colorado Anschutz School of Medicine and held senior roles at Duke University Health System, with nearly 300 peer-reviewed publications showcasing his expertise in advancing new therapies for neurologic diseases.
- Strategic Alignment: His deep expertise in oncology, neuroscience, and personalized medicine aligns closely with Labcorp's strategic focus, likely enhancing the value delivered to customers.
- Quality Compliance Committee: Following his appointment, Dr. Sampson was also appointed to the Quality and Compliance Committee, further strengthening Labcorp's leadership in quality management and compliance.
See More
Labcorp Appoints New Board Member
- New Board Member: Labcorp appointed Dr. John H. Sampson to its Board of Directors on February 9, 2026, leveraging his extensive experience in clinical care and biomedical research to advance the company's strategy in diagnostics and drug development.
- Academic Background: Dr. Sampson serves as vice chancellor and dean at the University of Colorado Anschutz School of Medicine, with nearly 300 peer-reviewed publications focused on advancing new therapies for neurologic diseases, enhancing Labcorp's expertise in personalized medicine and oncology.
- Leadership Experience: Prior to joining CU Anschutz, Dr. Sampson held senior vice president roles at Duke University Health System, where he led integrated practices, showcasing his strong background in large-scale health system leadership that aligns with Labcorp's strategic needs.
- Quality and Compliance Committee: Dr. Sampson's appointment to the Quality and Compliance Committee is expected to utilize his clinical and research experience to further Labcorp's mission of advancing early diagnosis and the development of new therapies.
See More
Labcorp Holdings Inc. to Release Q4 2025 Financial Results on February 17, 2026
- Earnings Release Schedule: Labcorp will release its Q4 2025 financial results before the market opens on February 17, 2026, expected to provide key financial metrics and business performance insights for investors to assess market standing.
- Conference Call Details: The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the financial results, enhancing transparency and engaging with investors directly.
- Investor Relations Website: The earnings press release and accompanying financial information will be posted on Labcorp's Investor Relations website, ensuring timely access to the latest information for all stakeholders and improving information accessibility.
- Replay Availability: A replay of the webcast will be available approximately two hours after the live event and will remain accessible until February 4, 2027, ensuring that investors who cannot participate live can still obtain important information.
See More
UniFirst Declares $0.365 Dividend, Kaiser Aluminum Announces $0.77 Dividend
- UniFirst Dividend Announcement: UniFirst's Board of Directors declared a quarterly cash dividend of $0.365 per share, payable on March 27, 2026, reflecting the company's ongoing profitability and commitment to shareholder returns.
- Kaiser Aluminum Dividend Declaration: Kaiser Aluminum announced a cash dividend of $0.77 per share, payable on February 13, 2026, demonstrating the company's strong performance in maintaining stable cash flow and shareholder returns.
- Agree Realty Dividend Increase: Agree Realty declared a monthly cash dividend of $0.262, with an annualized amount rising to $3.144, a 3.6% increase from Q1 2025, showcasing the company's focus on shareholder value and confidence in profit growth.
- Labcorp Dividend Payment: Labcorp Holdings announced a cash dividend of $0.72 per share, payable on March 12, 2026, indicating its robust financial performance in the innovative laboratory services sector.
See More
Labcorp Launches Alzheimer's Blood Test Nationwide
- Innovative Testing Tool: Labcorp's Elecsys® pTau-181 test is the first blood test cleared by the FDA for initial Alzheimer's disease assessment, enabling clinicians to rule out patients' Alzheimer's likelihood more quickly, thereby enhancing patient care efficiency.
- Wide Applicability: The test is now available nationwide in primary care settings, specifically designed for patients aged 55 and older experiencing cognitive decline symptoms, significantly expanding Labcorp's comprehensive portfolio of Alzheimer's blood tests.
- High Predictive Capability: The Elecsys pTau-181 test offers a 97.9% negative predictive value, allowing clinicians to confidently rule out Alzheimer's pathology, which is crucial in reducing unnecessary referrals amid a national shortage of neurologists.
- Convenient Testing Method: The test is performed via a simple blood draw, which can be done in a doctor's office or at any of Labcorp's over 2,200 patient service centers, providing a more accessible and cost-effective alternative to traditional brain scans or lumbar punctures.
See More
Labcorp Launches First Blood Test for Alzheimer's Disease
- First Blood Test: Labcorp's Elecsys® pTau-181 test is the first blood test cleared by the FDA for the initial assessment of Alzheimer's disease, representing a significant breakthrough in primary care that enables earlier identification of patient conditions.
- Expanded Testing Access: This test allows primary care clinicians to quickly rule out Alzheimer's disease when patients present cognitive symptoms, thereby enhancing patient care efficiency and reducing reliance on specialists, optimizing healthcare resource allocation.
- Market Demand Response: With approximately 7.2 million Americans living with Alzheimer's disease, Labcorp's launch of this test addresses the urgent need for early diagnosis and assessment, further solidifying its leadership position in the blood testing market for Alzheimer's disease.
- Research Support: Labcorp has supported over 90 Alzheimer's disease research protocols in the past five years, showcasing its deep expertise in biomarker development aimed at advancing early diagnosis and treatment progress for Alzheimer's disease.
See More
Labcorp Appoints New Board Member
- New Board Member: Labcorp appointed Dr. John H. Sampson to its Board of Directors effective February 9, 2026, bringing extensive experience in medicine and biomedical research, which is expected to advance the company's strategy in diagnostics and drug development.
- Professional Background: Dr. Sampson previously served as vice chancellor and dean at the University of Colorado Anschutz School of Medicine and held senior roles at Duke University Health System, with nearly 300 peer-reviewed publications showcasing his expertise in advancing new therapies for neurologic diseases.
- Strategic Alignment: His deep expertise in oncology, neuroscience, and personalized medicine aligns closely with Labcorp's strategic focus, likely enhancing the value delivered to customers.
- Quality Compliance Committee: Following his appointment, Dr. Sampson was also appointed to the Quality and Compliance Committee, further strengthening Labcorp's leadership in quality management and compliance.
See More
Labcorp Appoints New Board Member
- New Board Member: Labcorp appointed Dr. John H. Sampson to its Board of Directors on February 9, 2026, leveraging his extensive experience in clinical care and biomedical research to advance the company's strategy in diagnostics and drug development.
- Academic Background: Dr. Sampson serves as vice chancellor and dean at the University of Colorado Anschutz School of Medicine, with nearly 300 peer-reviewed publications focused on advancing new therapies for neurologic diseases, enhancing Labcorp's expertise in personalized medicine and oncology.
- Leadership Experience: Prior to joining CU Anschutz, Dr. Sampson held senior vice president roles at Duke University Health System, where he led integrated practices, showcasing his strong background in large-scale health system leadership that aligns with Labcorp's strategic needs.
- Quality and Compliance Committee: Dr. Sampson's appointment to the Quality and Compliance Committee is expected to utilize his clinical and research experience to further Labcorp's mission of advancing early diagnosis and the development of new therapies.
See More
Labcorp Holdings Inc. to Release Q4 2025 Financial Results on February 17, 2026
- Earnings Release Schedule: Labcorp will release its Q4 2025 financial results before the market opens on February 17, 2026, expected to provide key financial metrics and business performance insights for investors to assess market standing.
- Conference Call Details: The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the financial results, enhancing transparency and engaging with investors directly.
- Investor Relations Website: The earnings press release and accompanying financial information will be posted on Labcorp's Investor Relations website, ensuring timely access to the latest information for all stakeholders and improving information accessibility.
- Replay Availability: A replay of the webcast will be available approximately two hours after the live event and will remain accessible until February 4, 2027, ensuring that investors who cannot participate live can still obtain important information.
See More
UniFirst Declares $0.365 Dividend, Kaiser Aluminum Announces $0.77 Dividend
- UniFirst Dividend Announcement: UniFirst's Board of Directors declared a quarterly cash dividend of $0.365 per share, payable on March 27, 2026, reflecting the company's ongoing profitability and commitment to shareholder returns.
- Kaiser Aluminum Dividend Declaration: Kaiser Aluminum announced a cash dividend of $0.77 per share, payable on February 13, 2026, demonstrating the company's strong performance in maintaining stable cash flow and shareholder returns.
- Agree Realty Dividend Increase: Agree Realty declared a monthly cash dividend of $0.262, with an annualized amount rising to $3.144, a 3.6% increase from Q1 2025, showcasing the company's focus on shareholder value and confidence in profit growth.
- Labcorp Dividend Payment: Labcorp Holdings announced a cash dividend of $0.72 per share, payable on March 12, 2026, indicating its robust financial performance in the innovative laboratory services sector.
See More
